Original ArticleGenetic Analysis of Uveal Melanoma in 658 Patients Using the Cancer Genome Atlas Classification of Uveal Melanoma as A, B, C, and D
Section snippets
Methods
The medical and imaging records of all patients diagnosed with UM at the Ocular Oncology Service, Wills Eye Hospital, Thomas Jefferson University, Philadelphia, Pennsylvania, from October 1, 2008, through December 31, 2018, were reviewed. All patients with UM who completed FNAB for genetic analysis (analysis of chromosomes 3 and 8) were included. Patients without complete genetic analysis, including both chromosomes 3 and 8, were excluded. This study was conducted in accordance with the
Results
One thousand five tumors from 1304 patients were treated with plaque radiotherapy during the study period. Six hundred forty-six patients were excluded because of insufficient sample for genetic analysis, only chromosome 3 analysis, or declination of genetic testing. Six hundred fifty-eight tumors from 658 patients were able to be classified according to TCGA classification into class A (n = 342 [52%]), B (n = 91 [14%]), C (n = 118 [18%]), and D (n = 107 [16%]), as described in Table 1.
Discussion
Despite excellent local ocular tumor control for primary UM in the era of plaque radiotherapy, death resulting from metastatic disease remains prevalent, with metastasis in nearly 50% of all patients.15 Although clinical tumor features have prognostic value in UM, the oncology landscape has shifted toward genetic testing for cancer prognostication, and clinical trial eligibility for novel therapies that could prevent metastasis often depends on genetic testing results. Therefore, to identify
References (24)
- et al.
Cytogenetic abnormalities in uveal melanoma based on tumor features and size in 1059 patients: the 2016 W. Richard Green Lecture
Ophthalmology
(2017) - et al.
Uveal melanoma: trends in incidence, treatment, and survival
Ophthalmology
(2011) - et al.
Tumor doubling times in metastatic malignant melanoma of the uvea: tumor progression before and after treatment
Ophthalmology
(2000) - et al.
Chromosomal aberrations defining uveal melanoma of poor prognosis
Lancet
(1992) - et al.
Collaborative Ocular Oncology Group report number 1: prospective validation of a multi-gene prognostic assay in uveal melanoma
Ophthalmology
(2012) - et al.
Personalized prognosis of uveal melanoma based on cytogenetic profile in 1059 patients over an 8-year period: the 2017 Harry S. Gradle Lecture
Ophthalmology
(2017) - et al.
The Cancer Genome Atlas Project: an integrated molecular view of uveal melanoma
Ophthalmology
(2018) - et al.
Integrative analysis identifies four molecular and clinical subsets in uveal melanoma
Cancer Cell
(2017) - et al.
Comprehensive genetic landscape of uveal melanoma by whole-genome sequencing
Am J Hum Genet
(2016) - et al.
Small choroidal melanoma with chromosome 3 monosomy on fine-needle aspiration biopsy
Ophthalmology
(2007)
Clinical, histopathological and cytogenetic prognosticators in uveal melanoma—a comprehensive review
Anticancer Res
Age, survival predictors, and metastatic death in patients with choroidal melanoma: tentative evidence of a therapeutic effect on survival
JAMA Ophthalmol
Cited by (0)
Financial Disclosure(s): The author(s) have no proprietary or commercial interest in any materials discussed in this article.
Supported in part by the Eye Tumor Research Foundation, Philadelphia, Pennsylvania (C.L.S.). The funders had no role in the design and conduct of the study; in the collection, analysis, and interpretation of the data; or in the preparation, review, or approval of the manuscript. Carol L. Shields, MD, has had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
HUMAN SUBJECTS: Human subjects were included in this study. The human ethics committees at Wills Eye Hospital approved the study. All research adhered to the tenets of the Declaration of Helsinki. All participants provided informed consent.
No animal subjects were included in this study.
Author Contributions:
Conception and design: Vichitvejpaisal, Dalvin, Mazloumi, Shields
Analysis and interpretation: Vichitvejpaisal, Dalvin, Mazloumi, Ewens, Ganguly, Shields
Data collection: Vichitvejpaisal, Ewens, Ganguly
Obtained funding: Shields
Overall responsibility: Vichitvejpaisal, Dalvin, Mazloumi, Ewens, Ganguly, Shields